How Will Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% Change Your Treatment Paradigm?

Glaucoma experts share their real world experience with the first and only fixed-dose combination of a Rho kinase (ROCK) inhibitor and a prostaglandin analog.

aerie Pharmaceuticals, Inc.


These videos reflect the views and experiences of the participating physicians.
These physicians are paid consultants of Aerie Pharmaceuticals and have been compensated for their time.

Rocklatan


Your Colleagues Are Excited About Rocklatan®

Jody Piltz-Seymour, MD

Joseph Panarelli, MD

Rocklatan is a Fixed-Dose Combination of Rhopressa® and Latanoprost

Jody Piltz-Seymour, MD

Robert D. Fechtner, MD

Many of Your Patients Can Benefit from Rocklatan®

Joseph Panarelli, MD

Jody Piltz-Seymour, MD

Rocklatan® Can Simplify the Treatment Regimen

Robert D. Fechtner, MD

Jody Piltz-Seymour, MD

Rocklatan® and Rhopressa® Both Have Important Roles

Jody Piltz-Seymour, MD

Robert D. Fechtner, MD

Tell Your Patients What to Expect with Rocklatan®

Robert D. Fechtner, MD

Jody Piltz-Seymour, MD

Help Your Patients Gain Access to Rocklatan®

Joseph Panarelli, MD

Robert D. Fechtner, MD

Jody Piltz-Seymour, MD
Valley Eye Professionals, Huntington Valley, PA
Wills Eye Hospital Glaucoma Service
Clinical Professor, Perelman School of Medicine, University of Pennsylvania

Dr. Piltz-Seymour is a consultant and speaker for Aerie Pharmaceuticals.

Joseph Panarelli, MD
Chief, Division of Glaucoma Services, NYU Langone Health Center
Associate Professor, Department of Ophthalmology
Glaucoma Fellowship Director

Dr. Panarelli is a consultant to Allergan, Santen, Glaukos, and New World Medical and is a speaker for Aerie Pharmaceuticals and Allergan.

Robert D. Fechtner, MD
Professor and Chair, Department of Ophthalmology and Visual Sciences
SUNY Upstate Medical University
Syracuse, NY

Dr. Fechtner is a consultant to Aerie Pharmaceuticals, Alcon, Glaukos, New World Medical, Nicox, and Novartis and is a speaker for Aerie Pharmaceuticals.

IMPORTANT SAFETY INFORMATION

Contraindications
None

Warnings and Precautions

 

Adverse reactions:
ROCKLATAN®: The most common ocular adverse reaction is conjunctival hyperemia (59%). Five percent of patients discontinued therapy due to conjunctival hyperemia. Other common ocular adverse reactions were: instillation site pain (20%), corneal verticillata (15%), and conjunctival hemorrhage (11%). Eye pruritus, visual acuity reduced, increased lacrimation, instillation site discomfort, and blurred vision were reported in 5-8% of patients.

Netarsudil 0.02%: Instillation site erythema, corneal staining, increased lacrimation and erythema of eyelid.

Latanoprost 0.005%: Foreign body sensation, punctate keratitis, burning and stinging, itching, increased pigmentation of the iris, excessive tearing, eyelid discomfort, dry eye, eye pain, eyelid margin crusting, erythema of the eyelid, upper respiratory tract infection/nasopharyngitis/influenza, photophobia, eyelid edema, myalgia/arthralgia/back pain, and rash/allergic reaction.

INDICATIONS AND USAGE
ROCKLATAN® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is approved for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

DOSAGE AND ADMINISTRATION
The recommended dosage is one drop in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose in the evening. The dosage of ROCKLATAN® should not exceed once daily. ROCKLATAN® may be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.

Please click here for full prescribing information for ROCKLATAN® Solution

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit fda.gov/medwatch or call 1-800-FDA-1088.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Bacterial Keratitis: There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface.

Contact Lenses: Contact lenses should be removed prior to using RHOPRESSA® and may be reinserted 15 minutes following its administration.

ADVERSE REACTIONS:
The most common ocular adverse reaction observed in controlled clinical studies with RHOPRESSA® dosed once daily was conjunctival hyperemia, reported in 53% of patients. Six percent of patients discontinued therapy due to conjunctival hyperemia. Other common (approximately 20%) adverse reactions were: corneal verticillata, instillation site pain, and conjunctival hemorrhage. Instillation site erythema, corneal staining, blurred vision, increased lacrimation, erythema of eyelid, and reduced visual acuity were reported in 5-10% of patients.

The corneal verticillata seen in RHOPRESSA®-treated patients were first noted at 4 weeks of daily dosing. This reaction did not result in any apparent visual functional changes. Most corneal verticillata resolved upon discontinuation of treatment.

INDICATIONS AND USAGE
RHOPRESSA® (netarsudil ophthalmic solution) 0.02% is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

DOSAGE AND ADMINISTRATION
The recommended dosage is one drop in the affected eye(s) once daily in the evening.
 

Please see full Rhopressa Prescribing Information at www.rhopressa.com.